Drug Updates

Skip to main content

Drug Updates, FDA Approvals, Payers' Guide

Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer

Drug Updates, FDA Approvals, Payers' Guide

Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia

Drug Updates, FDA Approvals, Payers' Guide

Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Competition Heats Up in Rheumatoid Arthritis and Other Autoimmune Conditions

Gary Branning, MBA

Drug Updates, FDA Approvals, Payers' Guide

Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Select Drug Profiles

Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer

Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder

1
2
3
4
5
6
7

Page 4 of 8
Results 31 - 40 of 80